Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.7173-51-5,N-Decyl-N,N-dimethyldecan-1-aminium chloride,as a common compound, the synthetic route is as follows.

Didecyldimethylammonium chloride (0.02 mol) was dissolved in distilled water and 0.015 mol of benzoic acid sodium salt was added. The solution was stirred at 80 C. for 7 h. The reaction mixture was extracted by chloroform. Chloroform phase was removed and washed with distilled, cold water until chloride ions were no longer detected using AgNO3. Then chloroform was removed. Obtainede benzoate in 85% yield was dried in vacuum. 1H NMR and 13C NMR (CDCl3) were obtained.

7173-51-5 N-Decyl-N,N-dimethyldecan-1-aminium chloride 23558, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Rogers, Robin D.; Daly, Daniel T.; Swatloski, Richard P.; Hough, Whitney L.; Davis, James Hilliard; Smiglak, Marcin; Pernak, Juliusz; Spear, Scott K.; US2007/93462; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

56-54-2, (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A solution of quinine/quinidine 5 in dry DMF (4 mL/mmol 5) was treated with dry NaH (2.8 equiv.) and the resulting mixture was stirred at r.t. for 2 h. Benzyl chloride or allyl bromide (1.1 equiv.) were added and the resulting mixture was stirred at r.t. for 20 h. After extraction with brine and EtOAc the organic phase was dried over Na2SO4, filtrated and evaporated to dryness, giving 9-O-allylated or 9-O-benzylated compounds 6 [26] in >87% yield and sufficient purity for the following steps.

The synthetic route of 56-54-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Schoergenhumer, Johannes; Otte, Stefan; Haider, Victoria; Novacek, Johanna; Waser, Mario; Tetrahedron; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4199-88-6,5-Nitro-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: [(eta3-C3H5)Mo(CO)2(NCMe)2Cl] (1; 200 mg; 0.64 mmol) was dissolved in CH2Cl2 (50 mL) and treated with 5-nitro-1,10-phenanthroline (145 mg, 0.64 mmol). The solution was stirred for 30 min at room temperature. After that, the solvent was vacuum evaporated. The crude product was washed with ether and recrystallized from the mixture CH2Cl2/ether and vacuum dried. Yield: 270 mg (93%, 0.60 mmol). Anal. Calcd for C17H12ClMoN3O4: C, 45.00; H, 2.67; N, 9.26. Found: C, 45.12; H, 2.70; N, 9.23. 1H NMR (d6-acetone, 400 MHz, 25 C, delta ppm): 9.45-9.40 (m, 2H,C12H7N2), 9.24 (d, J(1H,1H) = 8.2 Hz, 1H, C12H7N2), 9.16 (s, 1H, C12H7N2), 9.06 (d, J(1H,1H) = 8.2 Hz, 1H, C12H7N2), 8.19 (s, 1H, C12H7N2), 3.35 (m, 1H, C3H5), 3.29 (d, J(1H,1H) = 6.2 Hz, 2H, C3H5), 1.37 (d, J,(1H,1H) = 8.7 Hz, 2H, C3H5). FTIR (ATR, cm-1): 1930 vs [nua(CO)], 1842 vs [nus(CO)], 1540 [nus(NO)], 1535 [nua(NO)].

As the paragraph descriping shows that 4199-88-6 is playing an increasingly important role.

Reference£º
Article; Honzi?ek, Jan; Vinklarek, Jaromir; Pad?lkova, Zde?ka; ?ebestova, Lucie; Foltanova, Karolina; ?eza?ova, Martina; Journal of Organometallic Chemistry; vol. 716; (2012); p. 258 – 268;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(7) To a solution of tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (5.9 mg) and compound (Z6) (6.7 mg) in NMP (200 muL) and DIEA (20 muL), HBTU (5.2 mg) was added, and the mixture was stirred at room temperature for 50 minutes. Methanol (100 muL) was added thereto, and then, the mixture was purified by preparative HPLC to obtain compound (Z7) (3.9 mg). LC/MS (ACQUITY) rt (min): 1.08 MS (ESI, m/z): 763.9 [M+2H]2+

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; FUJIFILM Corporation; FUJIFILM RI PHARMA CO., LTD.; FUKUNAGA, Hirofumi; DOZONO, Hiroyuki; HINO, Akihiro; OSHIKIRI, Shinobu; NAGANO, Akio; (99 pag.)US2016/199520; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

33454-82-9, Lithium trifluoromethanesulfonate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Was prepared in substantially the same manner as in Production Example 1, except that lithium trifluoromethanesulfonate (LiSO3CF3) was used instead of lithium bis (trifluoromethanesulfonyl) imide [Li (CF3SO2) 2N] Method 3 (CV-SO3CF3) was obtained. Was prepared in substantially the same manner as in Production Example 1, except that lithium trifluoromethanesulfonate (LiSO3CF3) was used instead of lithium bis (trifluoromethanesulfonyl) imide [Li (CF3SO2) 2N] Method 3 (CV-SO3CF3) was obtained.0.0005 mol (0.2 g) of crystal violet (Methyl violet 10B, anhydrous basis, purchased from Aldrich), which is an ionic dye containing chloride ion (Cl-), and lithium bis (trifluoromethanesulfonyl) imide (trifluoromethanesulfonyl) imide, 0.002 mol (0.57 g) of Li (CF3SO2) 2N] was added to 20 mL of acetone, and the mixture was stirred at room temperature for 3 hours. 100 mL of dichloromethane was added to the stirred mixture, and the mixture was stirred for 30 minutes. Then, 100 mL of distilled water was added to wash excess ions, and washing with distilled water was repeated three times. After the washing step, 3 g of magnesium sulfate (MgSO4) was added to remove moisture. After filtration, sample 1 (CV-N (SO2CF3) 2) was obtained (0.22 g, yield 60%) after evaporation of the solvent using a rotary evaporator

As the paragraph descriping shows that 33454-82-9 is playing an increasingly important role.

Reference£º
Patent; Kyungpook National University Industry-Academic Cooperation Foundation; Kim Seong-hun; (14 pag.)KR2018/1157; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

23616-79-7, N-Benzyl-N,N-dibutylbutan-1-aminium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 6 P-NITROBENZYL (5R,6R)-6-(2′,2′-DIMETHYL-3′-NITROSO-5′-OXO-4′-PHENYL-IMIDAZOLIDIN-1′-YL)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO[3,2,0]HEPTANE-2-CARBOXYLATE (X) A mixture of 4.2 g (10 mmol) of (5R,6R,4’R)-6-(2′,2′-dimethyl-3′-nitroso-5′-oxo-4′-phenyl-imidazolidin-1′-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3,2,0]heptane-2-carboxylic acid, 0.9 g (11 mmol) of sodium bicarbonate, 3.4 g (11 mmol) of benzyltributylammonium chloride, 2.16 g (10 mmol) of p-nitrobenzyl bromide and 42 ml of acetonitrile are stirred at room temperature for 1 hour. Then 50 ml of water are added and extraction is carried out with ethyl acetate. The extracts are washed successively with water and a saturated sodium chloride solution. Drying over anhydrous magnesium sulphate and subsequent evaporation are carried out, thereby obtaining the title product in the form of a solid.

The synthetic route of 23616-79-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Antibioticos, S.A.; US5229509; (1993); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4199-88-6, 5-Nitro-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Methanolic solution of CuCl22H2O (1.5 mmol) was added to methanolic solution of neutral bidentate ligand An(1.5 mmol), followed by the addition of a previously prepared methanolic solution of ciprofloxacin (1.5 mmol) in presence of CH3ONa (1.5 mmol). The reaction mixture was adjusted to ~6 pH. The resulting solution was refluxed for 1 h on a steam bath, followed by concentrating it to half of its volume. A fine amorphous product of green color obtained was washed with methanol followed by ether/hexane and was dried in vacuum desiccators. The proposed reaction for the synthesis of complexes 1-5 is shown in Scheme 1. All the synthesized complexes are soluble in DMSO. Elemental analysis data of synthesized complexes are kept in the Supplementary Material.

As the paragraph descriping shows that 4199-88-6 is playing an increasingly important role.

Reference£º
Article; Patel, Mohan N.; Gandhi, Deepen S.; Parmar, Pradhuman A.; Mehta, Jugal V.; Monatshefte fur Chemie; vol. 148; 5; (2017); p. 901 – 908;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4568-71-2, 3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(2) beta-(4-Fluorophenyl)-alpha-(2-methyl-1-oxopropyl)-gamma-oxobenzenebutanoic acid, ethyl ester A mixture of Part (1) compound (14.59 g, 55.4 mmoles), 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (4.484 g, 0.3 eq.) and triethylamine (5.4 mL, 0.7 eq.) was treated with benzaldehyde (1.9 mL), heated up to 70¡ã (oil bath) under argon and stirred at 70¡ã for 1.0 hour. The addition of benzaldehyde was repeated three more times (1.9 mL each), heating the mixture for 1.0 hour after each addition. The reaction mixture was cooled down to room temperature, diluted with ethyl acetate (800 mL) and washed successively with 5percent KHSO4 (150 mL), saturated sodium bicarbonate (150 mL) and brine (150 mL). The organic solution was dried (anhydrous MgSO4), filtered, evaporated to dryness and dried in vacuo . The crude product was combined with previous runs (881.6 mg and 236.5 mg) and chromatographed on a silica gel column (Merck), eluding the column with Et2O:Hexane mixtures (5:95; 1:9) to give title compound as a light yellow thick syrup (20.694 g, 98.3percent). TLC: Rf0.22 (Silica gel; Et2O:Hexane- 15:85; UV).

As the paragraph descriping shows that 4568-71-2 is playing an increasingly important role.

Reference£º
Patent; E.R. SQUIBB & SONS, INC.; EP463456; (1992); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

(NEt4)[OsNCl4] (50 mg, 0.85 mmol) was dissolved in 2 mL of acetone. To this, a solution of 4,7-diphenyl- I, 10-phenanthroline (85 mg, 2,55 mmol) in dichloromethane (5 mL) was added in a dropwise manner. The combined solutions were stirred at room temperature for 24 h. The resultant precipitate was filtered and washed with warm acetone, dichloromethane and diethyl ether. The osmium(VI) nitrido complex was isolated as a purple powder. Yield: 15 mg (27%). 1H NMR (400 MHz, DMSO-d6): delta 9.63 (d, 1H), 8.99 (d, 1H), 8.24 (m, 3H), 8.09 (d, 1H), 7.85 (m, 2H), 7.70 (m, 8H). 13C NMR (400 MHz, DMSO-d6): delta 156.2, 154.9, 151.7, 148.8, 144.5, 141.3, 135.5, 134.7, 134.2, 130.8, 130.5, 130.3, 129.7, 129.7, 129.2, 128.1, 128.1, 127.4, 126.7, 126.4. IR (KBr, cm”1): 1080.5 (OsN). Anal. Calcd. for 3, C24H16N30sCl3: C, 44.83; H, 2.51; N, 6.54. Found: C, 44.51; H, 2.27; N, 6.32.

1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; LIPPARD, Stephen, J.; SUNTHARALINGAM, Kogularamanan; (101 pag.)WO2016/4156; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.153-94-6,H-D-Trp-OH,as a common compound, the synthetic route is as follows.

General procedure: General procedure B A solution of amino nucleophile (3 equiv.), triethylamine (10 equiv.), and Intermediate 1 (1 equiv.) was stirred in dioxane and water (2:1 ratio) at 90 C until complete consumption of starting material was observed by LC/MS. The solution was diluted withiN hydrochloric acid and dichloromethane. The layers were then separated and thelayer was extracted with dichloromethane. The organics were combined, dried over magnesium sulfate, filtered, and the solvent was removed in vacuo. Purification yielded theproduct. The title compound was prepared following general procedure B, except D-tryptophan was the amine reactant and the contents were heated at 100 C for 18 h as a solution in THF/water (2:1). The contents were treated with 3N HC1 solution, solvent was removed in vacuo, and the resulting solid was washed with H20, then purified via reverse phase HPLC utilizing a 5-75 % acetonitrile/water gradient to deliver the desired compound, Compound 1-108 (3.5 mg, 16 %) as a clear oil.1H-NMR (500 MHz, CD3OD) oe 8.85 (d, 1 H), 8.16 (d, 1 H), 7.69 (d, 1 H), 7.33-7.27 (m, 1 H),7.17 (d, 1 H), 7.13-7.05 (m, 4 H), 7.01-6.96 (m, 1 H), 6.95-6.89 (m, 3 H), 5.97 (s, 2 H), 5.50 (dd, 1 H), 3.70 (dd, 1 H), 3.28 (d, 1 H).

As the paragraph descriping shows that 153-94-6 is playing an increasingly important role.

Reference£º
Patent; NAKAI, Takashi; MOORE, Joel; PERL, Nicholas Robert; IYENGAR, Rajesh R.; MERMERIAN, Ara; IM, G-Yoon Jamie; LEE, Thomas Wai-Ho; HUDSON, Colleen; RENNIE, Glen Robert; JIA, James; RENHOWE, Paul Allen; BARDEN, Timothy Claude; YU, Xiang Y; SHEPPECK, James Edward; IYER, Karthik; JUNG, Joon; WO2014/144100; (2014); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI